Fenofibrate
Fenofibrate (sold under the brand names Tricor, Fenobrat etc.), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. It is less commonly used compared than statins because it treats a different type of cholesterol abnormality to statins. While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol. Its use is recommended together with dietary changes.
| Clinical data | |
|---|---|
| Trade names | Fenoglide, Lipofen, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a601052 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | glucuronidation |
| Elimination half-life | 20 h |
| Excretion | urine (60%), feces (25%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.051.234 |
| Chemical and physical data | |
| Formula | C20H21ClO4 |
| Molar mass | 360.83 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 80 to 81 °C (176 to 178 °F) |
| |
| |
| (verify) | |
Common side effects include liver problems, breathing problems, abdominal pain, muscle problems, and nausea. Serious side effects may include toxic epidermal necrolysis, rhabdomyolysis, gallstones, and pancreatitis. Use during pregnancy and breastfeeding is not recommended. It works by multiple mechanisms.
It was patented in 1969, and came into medical use in 1975. It is available as a generic medication. In 2021, it was the 81st most commonly prescribed medication in the United States, with more than 8 million prescriptions.